tiprankstipranks
Trending News
More News >

Standard BioTools Approves Equity Plan Amendment at Meeting

Story Highlights
Standard BioTools Approves Equity Plan Amendment at Meeting

Don’t Miss TipRanks’ Half-Year Sale

Standard BioTools ( (LAB) ) has provided an update.

Standard BioTools Inc. held its 2025 Annual Meeting of Stockholders on June 18, 2025, where stockholders approved an amendment to the company’s Amended and Restated 2011 Equity Incentive Plan, increasing the number of shares of common stock reserved for issuance by 17,400,000 shares. Additionally, the election of Class III directors, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm were also confirmed during the meeting.

The most recent analyst rating on (LAB) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Spark’s Take on LAB Stock

According to Spark, TipRanks’ AI Analyst, LAB is a Neutral.

Standard BioTools’ overall stock score reflects significant financial challenges, with persistent losses and cash flow issues being major concerns. While the technical analysis indicates a neutral trend, the valuation metrics highlight current profitability issues. Positive aspects include strategic initiatives and improved financial discipline, as noted in the earnings call.

To see Spark’s full report on LAB stock, click here.

More about Standard BioTools

Average Trading Volume: 1,273,310

Technical Sentiment Signal: Sell

Current Market Cap: $414M

For a thorough assessment of LAB stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1